Intracavernous Drug-Induced Erections in the Management of Male Erectile Dysfunction: Experience with 100 Patients
- 1 April 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 135 (4) , 704-706
- https://doi.org/10.1016/s0022-5347(17)45825-3
Abstract
A total of 100 men with organic impotence underwent a trial of intracavernous drug-induced erections with a mixture of papaverine (25 mg./ml) and phentolamine (0.8 mg./ml). The response rates, that is functional erections, were 100 percent in patients with neurogenic impotence, 65.7 percent in those with vasculogenic impotence, 90 percent in the undetermined group and 64.7 percent in the neurogenic/vascular impotence group. Of the responders 79.5 percent elected to practice self-injection as a method to restore erectile function. The dose required to obtain functional erections in the purely neurogenic impotence group was significantly lower than that required in other groups. Complications were few and included 4 patients with sustained erections that required intervention. Intracavernous injection of vasoactive drugs appears to have promising value in the treatment and differential diagnosis of erectile dysfunction.This publication has 6 references indexed in Scilit:
- Venous Leakage: Surgical Treatment of a Curable Cause of ImpotenceJournal of Urology, 1985
- Auto-Injection of the Corpus Cavernosum with a Vasoactive Drug Combination for Vasculogenic ImpotenceJournal of Urology, 1985
- Intracavernous Injection of Papaverine as a Diagnostic and Therapeutic Method in Erectile FailureAngiology, 1984
- Cavernosal Alpha-Blockade: A New Technique for Investigating and Treating Erectile ImpotenceThe British Journal of Psychiatry, 1983
- Vasculogenic Impotence: Role of the Pelvic Steal TestJournal of Urology, 1982
- THE MULTIDISCIPLINARY APPROACH TO VASCULOGENIC IMPOTENCE1981